Corona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expectations backed by robust subscriptions and profitability, while Wakefit’s muted GMP reflects cautious sentiment towards consumer-facing growth businesses, highlighting current investor preference for earnings visibility and consistency.
eMudhra shares crash another 4%, down 40% in 3 sessions. What’s behind this free fall?
eMudhra will exit its global SSL/TLS certificate business following a security incident involving compromised private keys linked to eight intermediate Certificate Authority certificates. The segment